Skip to main content

Research Repository

Advanced Search

Evaluating trastuzumab in the treatment of HER2 positive breast cancer

Jaques, Ryan; Xu, Sam; Matsakas, Antonios

Authors

Ryan Jaques



Abstract

© 2020, Histology and Histopathology. All rights reserved. The transmembrane oncoprotein HER2 is encoded by ERBB2 gene and overexpressed in around 20% of invasive breast cancers. It can be specifically targeted by Trastuzumab (Herceptin®), a humanised IgG1 antibody. Trastuzumab has been regarded as one of the most effective therapeutic drugs targeted to HER2 positive cancers. However, there are drawbacks, notably cardiotoxicity and resistance, which have raised awareness in clinical use. Therefore, understanding the mechanism of action is vital to establish improved therapeutic strategies. Here we evaluate Trastuzumab application in the treatment of HER2 positive breast cancer, focusing on its mechanistic actions and clinical effectiveness. Alternative therapies targeting the HER2 receptor and its downstream anomalies will also be discussed, as these could highlight further targets that could be key to improving clinical outcomes.

Citation

Jaques, R., Xu, S., & Matsakas, A. (2020). Evaluating trastuzumab in the treatment of HER2 positive breast cancer. Histology and Histopathology, 35(10), 1059-1075. https://doi.org/10.14670/HH-18-221

Journal Article Type Review
Acceptance Date Apr 23, 2020
Online Publication Date Dec 4, 2020
Publication Date 2020-10
Deposit Date May 25, 2022
Publicly Available Date Jun 23, 2022
Journal Histology and Histopathology
Print ISSN 0213-3911
Electronic ISSN 1699-5848
Publisher Universidad de Murcia
Peer Reviewed Peer Reviewed
Volume 35
Issue 10
Pages 1059-1075
DOI https://doi.org/10.14670/HH-18-221
Keywords Breast cancer; Herceptin; Trastuzumab; Immunotherapy; HER2
Public URL https://hull-repository.worktribe.com/output/3681892

Files






You might also like



Downloadable Citations